Total submissions: 17
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV004732473 | SCV005367692 | likely pathogenic | RASopathy | 2024-09-17 | reviewed by expert panel | curation | The NM_006767.4:c.1084C>T (p.Arg362Ter) variant in LZTR1 is a nonsense variant predicted to cause a premature stop codon in biologically relevant exon 10/21 and lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). The highest population filtering allele frequency in gnomAD v2.1 is 0.00003426 (15/251042 alleles) in the European (non-Finnish) population. Evidence supports that this variant is associated with AR NS and is not associated with AD NS. This variant has been detected in 1 individual with NS. That individual was compound heterozygous for the variant and another loss of function pathogenic variant confirmed in trans by parental testing (c.1149+1G>T) (PM3, PMID:31182298). Schwannomatosis has been observed in individuals harboring this variant (PMID:29384852). In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: PM3, PVS1. (RASopathy VCEP specifications version 1.1; 9/17/2024). |
Eurofins Ntd Llc |
RCV000329167 | SCV000344439 | pathogenic | not provided | 2016-08-03 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763074 | SCV000893584 | pathogenic | Schwannomatosis 2; Noonan syndrome 10 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193024 | SCV001361558 | likely pathogenic | Schwannomatosis | 2019-11-25 | criteria provided, single submitter | clinical testing | Variant summary: LZTR1 c.1084C>T (p.Arg362X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Germline loss of function mutations in LZTR1 have been reported to predispose to an inherited disorder of multiple schwannomas (Piotrowski_2014). The variant allele was found at a frequency of 6e-05 in 251042 control chromosomes (gnomAD). As a gene with a pLI score of 0 (gnomAD) this gene is expected to be tolerant to loss of function variants. Therefore, this frequency does not allow any conclusions about variant significance in relation to Schwannomatosis. The variant, c.1084C>T, has been reported in the literature in individuals affected with Schwannomatosis (Jordan_2018, Louvrier_2018) as well as one individual in the 1000 Genome cohort without phenotypic information (Piotrowski_2014) and in a sequencing study of healthy participants (Hou_2018). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Labcorp Genetics |
RCV000329167 | SCV001406539 | pathogenic | not provided | 2024-01-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg362*) in the LZTR1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LZTR1 are known to be pathogenic (PMID: 24362817, 25335493, 25480913, 25795793, 29469822, 30368668, 30442762, 30442766, 30481304, 30859559). This variant is present in population databases (rs189150283, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with schwannomatosis and autosomal recessive Noonan syndrome (PMID: 29384852, 31182298). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 289969). For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV001706423 | SCV001934511 | pathogenic | Noonan syndrome 2 | 2020-09-08 | criteria provided, single submitter | clinical testing | This variant was identified as compound heterozygous with NM_006767.3:c.347C>G. |
Institute of Human Genetics, |
RCV001799649 | SCV002044431 | likely pathogenic | Schwannomatosis 2 | 2021-11-23 | criteria provided, single submitter | clinical testing | _x000D_ Criteria applied: PVS1, PS4_SUP |
Genome Diagnostics Laboratory, |
RCV001813447 | SCV002060661 | likely pathogenic | Noonan syndrome and Noonan-related syndrome | 2020-04-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000329167 | SCV002102605 | likely pathogenic | not provided | 2024-02-12 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Occurred with another LZTR1 variant on the opposite allele (in trans) in a patient with features consistent with a RASopathy in published literature (PMID: 31182298); This variant is associated with the following publications: (PMID: 31980526, 35840934, Santoro2021[abstract], 35251316, 29409008, 34308104, 29384852, 31182298, 38333672, 36113475) |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV002252087 | SCV002522823 | pathogenic | See cases | 2021-09-15 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PVS1, PS4, PM2, PM3 |
Ambry Genetics | RCV002429235 | SCV002727316 | pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-01-31 | criteria provided, single submitter | clinical testing | The p.R362* pathogenic mutation (also known as c.1084C>T), located in coding exon 10 of the LZTR1 gene, results from a C to T substitution at nucleotide position 1084. This changes the amino acid from an arginine to a stop codon within coding exon 10. This alteration has been reported in an individual with clinically diagnosed schwannomatosis as well as in a patient with autosomal recessive Noonan syndrome (Jordan JT et al. Medicine (Baltimore), 2018 Feb;97:e9717; Perin F et al. Rev Esp Cardiol (Engl Ed), 2019 Nov;72:978-980). Loss-of-function variants in LZTR1 are related to an increased risk for schwannomas and autosomal recessive Noonan syndrome; however, such associations with autosomal dominant Noonan syndrome have not been observed (Piotrowski A et al. Nat Genet. 2014 Feb;46:182-7; Yamamoto GL et al. J Med Genet. 2015 Jun;52:413-21; Johnston JJ et al. Genet Med. 2018 10;20:1175-1185). Based on the supporting evidence, this variant is pathogenic for an increased risk of LZTR1-related schwannomatosis (SWN) and would be expected to cause autosomal recessive Noonan syndrome when present along with a second pathogenic or likely pathogenic variant on the other allele; however, the association of this alteration with autosomal dominant Noonan syndrome is unlikely. |
Greenwood Genetic Center Diagnostic Laboratories, |
RCV003387519 | SCV004099262 | pathogenic | Noonan syndrome 10 | 2023-07-05 | criteria provided, single submitter | clinical testing | PVS1, PM2, PM3 |
Baylor Genetics | RCV001799649 | SCV004193671 | pathogenic | Schwannomatosis 2 | 2023-05-04 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV001706423 | SCV005042835 | pathogenic | Noonan syndrome 2 | criteria provided, single submitter | clinical testing | ||
Juno Genomics, |
RCV001799649 | SCV005415677 | pathogenic | Schwannomatosis 2 | criteria provided, single submitter | clinical testing | PM2_Supporting+PVS1+PS4_Supporting+PM3+PP4 | |
Institute of Human Genetics, |
RCV000736158 | SCV000864455 | pathogenic | Short stature | 2001-11-18 | no assertion criteria provided | case-control | |
Zotz- |
RCV001799649 | SCV004099432 | pathogenic | Schwannomatosis 2 | 2023-10-30 | no assertion criteria provided | clinical testing |